Clinical Trials
134 trialsMAGE-A4ᶜ¹º³²T for Multi-Tumor
USWM, LLC (dba US WorldMeds)
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
Tivozanib + Enzalutamide in Adv Prostate Cancer
Massachusetts General Hospital
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology
TRAP
Royal Marsden NHS Foundation Trust
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
M.D. Anderson Cancer Center
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
M.D. Anderson Cancer Center
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Pfizer
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
University of Wisconsin, Madison
Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
Incyte Corporation
PAVO
Tempus AI
PANTHER
Duke University
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
Incyte Corporation
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Incyte Corporation
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Trishula Therapeutics, Inc.
CYCLONE 3
Eli Lilly and Company
PICSI-H
University of Washington
A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma
Amgen
A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
Bristol-Myers Squibb
AUREA
Spanish Oncology Genito-Urinary Group
PRESIDE
Astellas Pharma Inc
PICSI-H
University of Washington
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Elevation Oncology
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Kymab Limited
Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
Indiana University
Study of INCB086550 in Select Solid Tumors
Incyte Corporation
FCS2
University of Washington
Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer
Daiichi Sankyo
A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer
Astellas Pharma Inc
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Radiation Therapy Oncology Group
SELECT
Beth Israel Deaconess Medical Center
Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors
Pfizer
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
M.D. Anderson Cancer Center
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Pfizer
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
Altor BioScience
ERICA
University of Michigan Rogel Cancer Center
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
Eli Lilly and Company
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
NextCure, Inc.
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
Icahn School of Medicine at Mount Sinai
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
Tavanta Therapeutics
Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies
Processa Pharmaceuticals
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Rutgers, The State University of New Jersey
LODESTAR
pharmaand GmbH
Parsabiv-MBD
Columbia University
Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer
Fred Hutchinson Cancer Center
PIVOT-10
Nektar Therapeutics
PIVOT-02
Nektar Therapeutics